Vanessa's Comment:

Niraparib is a PARP inhibitor approved for ovarian cancer. It disrupts cancer cells' ability to repair DNA damage. In the Phase 0 part of this study, presumed newly-diagnosed glioblastoma patients were given the drug for 4 days prior to resection, and resected tumor tissue was then tested to measure drug accumulation. All Phase 0 patients (n=46) met the accumulation threshold. Of the 27 patients with MGMT-unmethylated tumors, 19 were enrolled in the Phase 2 part of the study, where they received niraparib during radiation followed by a maintenance phase of niraparib alone. Median overall survival was 20.3 months, which is significantly better than the historic median of only 12.3 months for unmethylated GBM. While this study was small, a larger Phase 3 study is being planned which will compare niraparib with temozolomide for newly diagnosed MGMT-unmethylated GBM (more here). 


Posted on: 05/27/2024

Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival of newly diagnosed glioblastoma patients

 


Click HERE to return to brain tumor news headlines.


Our privacy / cookie policy has changed.
Click HERE to read it!